Who Owns Enbrel?
Enbrel (etanercept) is a biologic medication for rheumatoid arthritis, psoriasis, and other autoimmune conditions, owned by Amgen Inc. (Nasdaq: AMGN). Originally developed by Immunex and acquired by Amgen in 2002, it became one of the highest-selling drugs in pharmaceutical history with peak annual sales exceeding $8 billion.
Parent Company
Acquired
2002
Status
Publicly Traded
Headquarters
Enbrel Timeline
Who Owns Enbrel?
- Parent Company: Amgen Inc.
- Ownership Type: Acquired
- Acquisition Year: 2002
- Company Type: Publicly Traded
- Stock Ticker: NASDAQ: AMGN
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Enbrel | Amgen Inc. | Acquired |
Where to Buy
Disclosure: We may earn commission from purchases
Enbrel on AmazonAdvertisement
History of Enbrel
- Founded: 1998
- Founders: Immunex Corporation (original developer)
- Acquired by Amgen Inc.: 2002
Immunex Corporation developed Enbrel (etanercept), a tumor necrosis factor (TNF) inhibitor, and won FDA approval in 1998 for rheumatoid arthritis, making it one of the first biologic disease-modifying treatments for the condition.
The drug transformed rheumatoid arthritis treatment, shifting patients from symptomatic management toward biologic intervention that could slow disease progression. It became a megablockbuster, eventually reaching peak annual sales exceeding $8 billion, among the highest for any drug in history.
Amgen's 2002 acquisition of Immunex brought Enbrel under its portfolio, and the drug became Amgen's largest product through the 2000s and 2010s. Additional indications including psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis expanded its reach.
Patent litigation and exclusivity extended the US market longer than international markets, where biosimilars launched earlier. US biosimilar competition arrived later as exclusivity periods ran out, beginning the decline from peak sales.
Advertisement
About Amgen Inc.
What does Amgen own?
Amgen owns the Amgen brand and product brands including Enbrel, Prolia, Otezla, Neulasta, Repatha, Tezspire, and others. The Horizon acquisition added Tepezza, Krystexxa, and Uplizna.
Is Amgen publicly traded?
Yes. Amgen trades on Nasdaq under ticker AMGN and is a component of the S&P 500 and Dow Jones Industrial Average.
Who founded Amgen?
George Rathmann founded Applied Molecular Genetics in 1980 in Thousand Oaks, California. The name Amgen derives from the original.
Where is Amgen headquartered?
Amgen is headquartered in Thousand Oaks, California, USA.
Advertisement
Who owns Amgen?
Amgen is owned by public shareholders with no controlling investor. Robert Bradway serves as Chairman and CEO.
What is Amgen's revenue?
Amgen reported FY2025 total revenues of $36.8 billion, up 10%, with GAAP net income of $7.7 billion and non-GAAP EPS of $21.84.
What does Amgen make?
Amgen makes biologic medicines including Enbrel for rheumatoid arthritis, Prolia for osteoporosis, Otezla for psoriasis, and oncology and rare disease treatments.
- Founded: 1980
- Headquarters: Thousand Oaks, California, USA
- Company Type: Publicly Traded
- Stock: NASDAQ: AMGN
- Revenue: $36.8 billion (FY2025)
- Employees: Approximately 28,000
Where Is Enbrel Made / Based?
- Headquarters: Thousand Oaks, California, USA (parent)
- Manufacturing / Operations: United States, Ireland
Enbrel Categories & Tags
Enbrel Recalls & Controversies
As a biologic medication, Enbrel's issues are drug pricing, safety labeling, and patent litigation.
Advertisement
Drug pricing: Enbrel's US list price has been a prominent example in drug pricing debates, cited frequently in discussions of pharmaceutical affordability and international price comparisons.
Patent litigation: Amgen's extended exclusivity defense for Enbrel produced significant patent litigation, with questions about the thicket of patents that delayed US biosimilar entry longer than in Europe.
Safety labeling: TNF inhibitors carry boxed warnings about infection and malignancy risk, the class-wide labeling Enbrel shares with competitors.
Advertisement
Brands Owned by Amgen Inc.
Healthcare PharmaceuticalsAmgen
Owned by Amgen Inc.
Master biotechnology brand of Amgen Inc., the world's largest independent biotech, covering its full portfolio of biologic medicines.
biotechnologypharmaceuticalsbiologics
Healthcare PharmaceuticalsNeulasta
Owned by Amgen Inc.
Biologic medication for chemotherapy-induced neutropenia owned by Amgen Inc., the leading white blood cell stimulator for cancer patients.
pharmaceuticalsbiologicsoncology
Healthcare PharmaceuticalsOtezla
Owned by Amgen Inc.
Oral medication for psoriasis and psoriatic arthritis owned by Amgen Inc., the leading non-injectable treatment in its class.
pharmaceuticalspsoriasispsoriatic-arthritis
Healthcare PharmaceuticalsProlia
Owned by Amgen Inc.
Biologic osteoporosis medication owned by Amgen Inc., the leading injectable treatment for bone density loss.
pharmaceuticalsbiologicsosteoporosis
Enbrel Ownership: Pros & Cons
Advantages
- +One of the highest-selling drugs in pharmaceutical history
- +Established safety profile from decades of use supports continued prescribing
- +Amgen's biologics manufacturing expertise ensures supply reliability
- +Still generates billions in annual sales even in decline phase
- +Brand recognition among rheumatologists is unmatched
Considerations
- -Sales declining from peak as newer agents and biosimilars take share
- -Medicare price negotiation compresses US economics
- -Patent exclusivity ended, exposing to biosimilar competition
- -Newer mechanisms offer better efficacy for many patients
- -IRA pricing trajectory will continue pressuring the brand
Advertisement
Frequently Asked Questions About Enbrel
Sources & Further Reading
Advertisement
Competitors to Enbrel
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Amgen | USA | 1980 | Market leader | Global | All-ages | |
| Amgen | USA (parent) | 2002 | Market leader | Global | All-ages | |
| Amgen | USA (parent) | 2010 | Market leader | Global | All-ages | |
| Bausch Health | Canada (Bausch Health Companies Inc.) | 1968 | Specialty | United states | Unisex | |
| Pfizer | USA | 2012 | Premium | Global | All Genders | |
| Amgen | USA (parent) | 2014 | Market leader | Global | All-ages |
Learn More About Competitors
Healthcare PharmaceuticalsAmgen
Owned by Amgen Inc.
Master biotechnology brand of Amgen Inc., the world's largest independent biotech, covering its full portfolio of biologic medicines.
biotechnologypharmaceuticalsbiologics
Healthcare PharmaceuticalsNeulasta
Owned by Amgen Inc.
Biologic medication for chemotherapy-induced neutropenia owned by Amgen Inc., the leading white blood cell stimulator for cancer patients.
pharmaceuticalsbiologicsoncology
Healthcare PharmaceuticalsProlia
Owned by Amgen Inc.
Biologic osteoporosis medication owned by Amgen Inc., the leading injectable treatment for bone density loss.
pharmaceuticalsbiologicsosteoporosis
Healthcare PharmaceuticalsAzasan
Owned by Bausch Health Companies Inc.
Bausch Health's branded azathioprine tablet (75 mg and 100 mg strengths), distributed by Salix Pharmaceuticals (a division of Bausch Health US, LLC) and manufactured by Alcami Corporation, indicated for renal transplant rejection prevention and severe rheumatoid arthritis, based on the immunosuppressant azathioprine originally developed by Nobel laureate Gertrude Elion at Burroughs Wellcome in the 1950s.
immunosuppressantazathioprinetransplant
Healthcare PharmaceuticalsXeljanz
Owned by Pfizer Inc.
Pfizer's oral JAK inhibitor (tofacitinib) approved by the FDA in 2012 for rheumatoid arthritis and other autoimmune conditions. Subject to a strengthened black box warning since September 2021.
immunologytofacitinibjak-inhibitor
Healthcare PharmaceuticalsOtezla
Owned by Amgen Inc.
Oral medication for psoriasis and psoriatic arthritis owned by Amgen Inc., the leading non-injectable treatment in its class.
pharmaceuticalspsoriasispsoriatic-arthritis
Competitive Analysis
Market Positioning: Enbrel competes with 6 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Advertisement
Independent Alternatives to Enbrel
Looking for brands with different ownership structures? These similar brands are not owned by Amgen Inc., giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsNovo Nordisk
Owned by Novo Nordisk
Danish pharmaceutical company specializing in diabetes care and obesity treatment. Founded in 1923, headquartered in Bagsvaerd, Denmark. World leader in diabetes care and a leader in obesity treatment with Ozempic, Wegovy, and the investigational CagriSema. CEO Lars Fruergaard Jorgensen departed in March 2025; interim leadership under board chairman Helge Lund until a permanent CEO is appointed.
pharmaceuticalsdiabetesobesity
Publicly Traded
Novo Nordisk operates independently without a large parent corporation.
Healthcare PharmaceuticalsStryker
Owned by Stryker Corporation
Flagship medical technology brand of Stryker Corporation, founded in 1941 and a global leader in orthopaedic implants and surgical equipment.
medical-devicesorthopaedicssurgical-equipment
Publicly Traded
Stryker operates independently without a large parent corporation.
Healthcare PharmaceuticalsRegeneron
Owned by Regeneron Pharmaceuticals, Inc.
Biotechnology brand of Regeneron Pharmaceuticals, developer of Eylea, Dupixent, and Libtayo, headquartered in Tarrytown, New York.
biotechnologypharmaceuticalseylea
Publicly Traded
Regeneron operates independently without a large parent corporation.
Healthcare PharmaceuticalsAlcon
Owned by Alcon Inc.
Independent publicly traded global eye care company headquartered in Geneva, Switzerland, specializing in surgical equipment, contact lenses, and ophthalmic products. Spun off from Novartis in April 2019.
eye-carecontact-lensesophthalmic
Publicly Traded
Alcon operates independently without a large parent corporation.
Healthcare PharmaceuticalsAvaility
Owned by Availity
The largest real-time health information network in the US, owned by a consortium of major health insurers and Novo Holdings.
healthcare-technologyclearinghouseclaims-processing
Privately Owned
Availity is privately owned, unlike Enbrel which is under a publicly traded parent company.
Healthcare PharmaceuticalsBand-Aid
Owned by Kenvue
American adhesive bandage brand invented in 1921, owned by Kenvue Inc. Band-Aid is the leading adhesive bandage brand in the United States and is sold in more than 100 countries.
wound-careadhesive-bandagefirst-aid
Privately Owned
Band-Aid is privately owned, unlike Enbrel which is under a publicly traded parent company.
Amgen Inc. Stock Information
Advertisement
Jobs at Amgen Inc.
Latest News About Enbrel
Advertisement
Related Articles About Enbrel
View more articles
News & Updates
Monthly IPO Roundup: November 2026 -- October's Biggest Listings
October 2026 IPOs: Jio Platforms set India's all-time record at $3.2B and surged 27%, GCash owner Mynt raised a Philippine-record P60.9B, Anthropic filed publicly for a possible mid-November debut, and U.S. listings were a biotech grab bag. Full recap.
Who Brands StaffNov 6, 2026
Ipo RoundupIpoStock Market
News & Updates
Monthly M&A Roundup: October 2026 Brand Ownership Changes
October 2026's biggest deals: Paramount Skydance closed its $110B Warner Bros. Discovery takeover, Salesforce signed Braze for $5.66B, Proofpoint bought Varonis for $6.3B, the Weston family agreed to buy Boots for $8.9B, and Viatris added Pacira for $1.65B. Full breakdown.
Who Brands StaffNov 6, 2026
M And A RoundupAcquisitionsNews
Rivalry
Duracell vs Energizer: The Battery Brand Rivalry
Duracell is Berkshire Hathaway-owned (25-30% US share). Energizer is publicly traded (NYSE: ENR) with Rayovac. Together they control ~85% of branded US batteries, but Amazon Basics has 27.1% online. Explore our database.
Who Brands StaffOct 23, 2026
DuracellEnergizerRivalry
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Brandpharmaceutical
Abbokinase
Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.
Brand in Healthcare & Pharmaceuticals
thrombolyticurokinase
Brandrsv-vaccine
Abrysvo
Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.
Brand in Healthcare & Pharmaceuticals
vaccinesmaternal-immunization
Brandspecialty-pharmacy
Accredo
Specialty pharmacy founded in 1996 in Memphis, serving patients with complex and rare conditions as the specialty pharmacy of Evernorth within The Cigna Group.
Brand in Healthcare & Pharmaceuticals
rare-diseaseevernorth